Cargando…

Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications

Peritonitis is a limiting complication of peritoneal dialysis, which is treated by intraperitoneal administration of antibiotics. Various dosing strategies are recommended for intraperitoneally administered vancomycin, which leads to large differences in intraperitoneal vancomycin exposure. Based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartinger, Jan Miroslav, Michaličková, Danica, Dvořáčková, Eliška, Hronová, Karolína, Krekels, Elke H. J., Szonowská, Barbora, Bednářová, Vladimíra, Benáková, Hana, Kroneislová, Gabriela, Závora, Jan, Tesař, Vladimír, Slanař, Ondřej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222948/
https://www.ncbi.nlm.nih.gov/pubmed/37242636
http://dx.doi.org/10.3390/pharmaceutics15051394
_version_ 1785049822494982144
author Hartinger, Jan Miroslav
Michaličková, Danica
Dvořáčková, Eliška
Hronová, Karolína
Krekels, Elke H. J.
Szonowská, Barbora
Bednářová, Vladimíra
Benáková, Hana
Kroneislová, Gabriela
Závora, Jan
Tesař, Vladimír
Slanař, Ondřej
author_facet Hartinger, Jan Miroslav
Michaličková, Danica
Dvořáčková, Eliška
Hronová, Karolína
Krekels, Elke H. J.
Szonowská, Barbora
Bednářová, Vladimíra
Benáková, Hana
Kroneislová, Gabriela
Závora, Jan
Tesař, Vladimír
Slanař, Ondřej
author_sort Hartinger, Jan Miroslav
collection PubMed
description Peritonitis is a limiting complication of peritoneal dialysis, which is treated by intraperitoneal administration of antibiotics. Various dosing strategies are recommended for intraperitoneally administered vancomycin, which leads to large differences in intraperitoneal vancomycin exposure. Based on data from therapeutic drug monitoring, we developed the first-ever population pharmacokinetic model for intraperitoneally administered vancomycin to evaluate intraperitoneal and plasma exposure after dosing schedules recommended by the International Society for Peritoneal Dialysis. According to our model, currently recommended dosing schedules lead to possible underdosing of a large proportion of patients. To prevent this, we suggest avoiding intermittent intraperitoneal vancomycin administration, and for the continuous dosing regimen, we suggest a loading dose of 20 mg/kg followed by maintenance doses of 50 mg/L in each dwell to improve the intraperitoneal exposure. Vancomycin plasma level measurement on the fifth day of treatment with subsequent dose adjustment would prevent it from reaching toxic levels in the few patients who are susceptible to overdose.
format Online
Article
Text
id pubmed-10222948
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102229482023-05-28 Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications Hartinger, Jan Miroslav Michaličková, Danica Dvořáčková, Eliška Hronová, Karolína Krekels, Elke H. J. Szonowská, Barbora Bednářová, Vladimíra Benáková, Hana Kroneislová, Gabriela Závora, Jan Tesař, Vladimír Slanař, Ondřej Pharmaceutics Article Peritonitis is a limiting complication of peritoneal dialysis, which is treated by intraperitoneal administration of antibiotics. Various dosing strategies are recommended for intraperitoneally administered vancomycin, which leads to large differences in intraperitoneal vancomycin exposure. Based on data from therapeutic drug monitoring, we developed the first-ever population pharmacokinetic model for intraperitoneally administered vancomycin to evaluate intraperitoneal and plasma exposure after dosing schedules recommended by the International Society for Peritoneal Dialysis. According to our model, currently recommended dosing schedules lead to possible underdosing of a large proportion of patients. To prevent this, we suggest avoiding intermittent intraperitoneal vancomycin administration, and for the continuous dosing regimen, we suggest a loading dose of 20 mg/kg followed by maintenance doses of 50 mg/L in each dwell to improve the intraperitoneal exposure. Vancomycin plasma level measurement on the fifth day of treatment with subsequent dose adjustment would prevent it from reaching toxic levels in the few patients who are susceptible to overdose. MDPI 2023-05-02 /pmc/articles/PMC10222948/ /pubmed/37242636 http://dx.doi.org/10.3390/pharmaceutics15051394 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hartinger, Jan Miroslav
Michaličková, Danica
Dvořáčková, Eliška
Hronová, Karolína
Krekels, Elke H. J.
Szonowská, Barbora
Bednářová, Vladimíra
Benáková, Hana
Kroneislová, Gabriela
Závora, Jan
Tesař, Vladimír
Slanař, Ondřej
Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
title Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
title_full Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
title_fullStr Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
title_full_unstemmed Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
title_short Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications
title_sort intraperitoneally administered vancomycin in patients with peritoneal dialysis-associated peritonitis: population pharmacokinetics and dosing implications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222948/
https://www.ncbi.nlm.nih.gov/pubmed/37242636
http://dx.doi.org/10.3390/pharmaceutics15051394
work_keys_str_mv AT hartingerjanmiroslav intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT michalickovadanica intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT dvorackovaeliska intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT hronovakarolina intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT krekelselkehj intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT szonowskabarbora intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT bednarovavladimira intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT benakovahana intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT kroneislovagabriela intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT zavorajan intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT tesarvladimir intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications
AT slanarondrej intraperitoneallyadministeredvancomycininpatientswithperitonealdialysisassociatedperitonitispopulationpharmacokineticsanddosingimplications